It has been found that inhibition of the PERK-ATF4 pathway can reduce the expression of Beclin1, an important protein involved in autophagy, thereby inhibiting autophagy increases the sensitivity of sorafenib to HCC cells [26, 36]. Here, ATF4 is linked to hepatocellular carcinoma.